Author | Tony Berberabe, MPH


Moving Chemotherapy Delivery to the Outpatient Setting Results in Substantial Savings

September 23, 2020

The impetus for taking a closer look at cancer drug spending starts with their costs. But the other side of the equation, the revenue coming in, can also be a factor that requires adjusting.

Stage Is Set for Exploring TNBC, HER2-Positive Settings at 38th Annual CFS

September 23, 2020

Delivering evidence-based state-of-the art cancer care in the management of hematologic and solid malignancies is the mainstay of the 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow conference taking place virtually November 4 through 6, 2020.

Adding Bevacizumab to Osimertinib Failed to Improve PFS in EGFR T790M+ Lung Cancer

September 21, 2020

Osimertinib plus bevacizumab did not lead to a prolonged progression-free survival compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M.

No PFS Improvement Is Seen With EGFR/VEGF Inhibitor Combo

September 20, 2020

Patients with advanced lung adenocarcinoma who harbor EGFR T790M mutations did not experience significant progression-free survival improvement with osimertinib plus bevacizumab versus osimertinib alone, according to findings presented by Yukihiro Toi, MD, during the 2020 European Society for Medical Oncology Virtual Congress.